Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $98,879 | 29 | 41.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $86,767 | 40 | 36.1% |
| Travel and Lodging | $51,552 | 83 | 21.4% |
| Food and Beverage | $3,345 | 86 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $187,036 | 163 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $29,897 | 41 | $0 (2019) |
| AbbVie Inc. | $14,955 | 24 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $8,600 | 6 | $0 (2017) |
| Janssen Biotech, Inc. | $17.99 | 1 | $0 (2018) |
| Braeburn Pharmaceuticals, Inc. | $13.54 | 1 | $0 (2017) |
| Sunovion Pharmaceuticals Inc. | $13.37 | 1 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $10.27 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $26,819 | 18 | Gilead Sciences, Inc. ($26,819) |
| 2022 | $27,895 | 19 | Gilead Sciences, Inc. ($27,895) |
| 2021 | $23,998 | 20 | Gilead Sciences, Inc. ($21,861) |
| 2020 | $16,488 | 21 | Gilead Sciences, Inc. ($13,638) |
| 2019 | $47,518 | 60 | Gilead Sciences, Inc. ($37,298) |
| 2018 | $49,808 | 55 | Gilead Sciences, Inc. ($29,058) |
| 2017 | $48,016 | 45 | Gilead Sciences Inc ($30,466) |
All Payment Transactions
238 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/03/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,736.00 | General |
| 05/16/2023 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $295.00 | General |
| 05/16/2023 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $295.00 | General |
| 04/21/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,070.00 | General |
| 03/30/2023 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $1,010.27 | General |
| 03/29/2023 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $177.76 | General |
| 03/29/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $47.38 | General |
| 03/29/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.23 | General |
| 03/28/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $47.87 | General |
| 03/14/2023 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $2,514.79 | General |
| 02/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,950.00 | General |
| Category: HCV | ||||||
| 02/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $1,753.80 | General |
| Category: HCV | ||||||
| 02/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $673.36 | General |
| Category: HCV | ||||||
| 02/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $550.00 | General |
| Category: HCV | ||||||
| 02/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $525.00 | General |
| Category: HCV | ||||||
| 02/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: HCV | ||||||
| 02/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $49.97 | General |
| Category: HCV | ||||||
| 02/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $49.97 | General |
| Category: HCV | ||||||
| 12/22/2022 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,544.00 | General |
| 12/15/2022 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,560.00 | General |
| 09/02/2022 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,560.00 | General |
| Category: HCV | ||||||
| 09/01/2022 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $420.19 | General |
| Category: HCV | ||||||
| 09/01/2022 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: HCV | ||||||
| 07/27/2022 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $405.00 | General |
| Category: HCV | ||||||
| 07/12/2022 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,320.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 15 | 36 | $12,780 | $3,622 |
| 2022 | 1 | 21 | 59 | $20,945 | $5,101 |
| 2021 | 2 | 37 | 69 | $26,795 | $6,610 |
| 2020 | 2 | 66 | 141 | $57,315 | $13,898 |
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 36 | $12,780 | $3,622 | 28.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 59 | $20,945 | $5,101 | 24.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 49 | $17,395 | $4,311 | 24.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 20 | $9,400 | $2,299 | 24.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 44 | 119 | $42,245 | $10,226 | 24.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 22 | 22 | $15,070 | $3,673 | 24.4% |
About Dr. Frederick Altice, MD
Dr. Frederick Altice, MD is a Infectious Disease healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1710960158.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frederick Altice, MD has received a total of $240,543 in payments from pharmaceutical and medical device companies, with $26,819 received in 2023. These payments were reported across 238 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($98,879).
As a Medicare-enrolled provider, Altice has provided services to 139 Medicare beneficiaries, totaling 305 services with total Medicare billing of $29,230. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location New Haven, CT
- Active Since 11/21/2005
- Last Updated 07/21/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1710960158
Products in Payments
- Epclusa (Drug) $59,707
- Veklury (Drug) $10,445
- Mavyret (Drug) $9,968
- ZEPATIER (Drug) $8,469
- Vosevi (Drug) $4,564
- MAVYRET (Drug) $3,800
- EVOTAZ (Drug) $500.00
- ISENTRESS (Drug) $129.76
- PREZCOBIX (Drug) $17.99
- Probuphine (Drug) $13.54
- LATUDA (Drug) $13.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in New Haven
Onyema Ogbuagu, Md, MD
Infectious Disease — Payments: $355,868
Mr. Michael Virata, Md, MD
Infectious Disease — Payments: $43,400
Dr. Sandra Springer, Md, MD
Infectious Disease — Payments: $31,969
Dr. Albert Ko, M.d, M.D
Infectious Disease — Payments: $31,109
Dr. Merceditas Villanueva, Md, MD
Infectious Disease — Payments: $8,909
Albert Shaw, Md, MD
Infectious Disease — Payments: $4,016